48 results on '"Kufner, Sebastian"'
Search Results
2. Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes
- Author
-
Lahu, Shqipdona, Ndrepepa, Gjin, Gewalt, Senta, Schüpke, Stefanie, Pellegrini, Costanza, Bernlochner, Isabell, Aytekin, Alp, Neumann, Franz-Josef, Menichelli, Maurizio, Richardt, Gert, Cassese, Salvatore, Xhepa, Erion, Kufner, Sebastian, Sager, Hendrik B., Joner, Michael, Ibrahim, Tareq, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, and Mayer, Katharina
- Published
- 2021
- Full Text
- View/download PDF
3. Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis.
- Author
-
Koch, Tobias, Lenz, Tobias, Rheude, Tobias, Cassese, Salvatore, Kazazi, Mej, Xhepa, Erion, Kessler, Thorsten, Wiebe, Jens, Ferenc, Miroslaw, Laugwitz, Karl-Ludwig, Joner, Michael, Schunkert, Heribert, Kastrati, Adnan, and Kufner, Sebastian
- Abstract
Treatment of patients with recurrence of in-stent restenosis (ISR) remains particularly challenging, with data and guideline recommendations for repeat percutaneous coronary intervention being scant. The aim of this study was to investigate the long-term incidence of recurrent revascularization events after percutaneous treatment of drug-eluting stent (DES) ISR. In this post hoc analysis, 402 patients (500 lesions) assigned to plain balloon (PB), drug-coated balloon (DCB), or DES treatment in the randomized ISAR-DESIRE 3 (Efficacy Study of Paclitaxel-Eluting Balloon, -Stent vs. Plain Angioplasty for Drug-Eluting Stent Restenosis) trial were followed up over a median of 10.3 years. The primary endpoint was total repeat target lesion revascularization (R-TLR) including all, first and recurrent, events. At the end of follow-up, first R-TLR was required in 204 lesions, 82 in the PB group, 70 in the DCB group, and 52 in the DES group. The total number of R-TLRs was 373: 162 in the PB group, 124 in the DCB group, and 87 in the DES group. During the first year of follow-up, the risk for total R-TLR was reduced by DCB (HR: 0.36; 95% CI: 0.24-0.54) and DES (HR: 0.23; 95% CI: 0.14-0.38) treatment compared with PB treatment. After 1 year, the risk for total R-TLR was nonsignificantly reduced by DCB treatment (HR: 0.77; 95% CI: 0.51-1.16) and significantly reduced by DES treatment (HR: 0.61; 95% CI: 0.39-0.95) compared with PB treatment. Risk in the DCB and DES groups was similar during (HR: 1.54; 95% CI: 0.89-2.69) and after (HR: 1.26; 95% CI: 0.82-1.92) 1 year. The total number of R-TLRs over 10 years after treatment of patients with DES ISR was high. DCBs and particularly DES were able to reduce the need for both first and recurrent revascularization compared with PB treatment. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study
- Author
-
Koppara, Tobias, Tada, Tomohisa, Xhepa, Erion, Kufner, Sebastian, Byrne, Robert A., Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Joner, Michael
- Published
- 2018
- Full Text
- View/download PDF
5. Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and ISAR-DESIRE 4) trials
- Author
-
Colleran, Roisin, Joner, Michael, Kufner, Sebastian, Altevogt, Felix, Neumann, Franz-Josef, Abdel-Wahab, Mohamed, Bohner, Janika, Valina, Christian, Richardt, Gert, Zrenner, Bernhard, Cassese, Salvatore, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, and Byrne, Robert A.
- Published
- 2018
- Full Text
- View/download PDF
6. Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation.
- Author
-
Coughlan, John Joseph, Maeng, Michael, Räber, Lorenz, Brugaletta, Salvatore, Aytekin, Alp, Okkels Jensen, Lisette, Bär, Sarah, Ortega-Paz, Luis, Laugwitz, Karl-Ludwig, Madsen, Morten, Heg, Dik, Sabaté, Manel, Kufner, Sebastian, Warnakula Olesen, Kevin Kris, Kastrati, Adnan, Windecker, Stephan, and Cassese, Salvatore
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
7. Rotational Atherectomy or Balloon-Based Techniques to Prepare Severely Calcified Coronary Lesions.
- Author
-
Rheude, Tobias, Fitzgerald, Sean, Allali, Abdelhakim, Mashayekhi, Kambis, Gori, Tommaso, Cuculi, Florim, Kufner, Sebastian, Hemetsberger, Rayyan, Sulimov, Dmitriy S., Rai, Himanshu, Ayoub, Mohamed, Bossard, Matthias, Xhepa, Erion, Fusaro, Massimiliano, Toelg, Ralph, Joner, Michael, Byrne, Robert A., Richardt, Gert, Kastrati, Adnan, and Cassese, Salvatore
- Abstract
The comparative efficacy of percutaneous techniques for the preparation of calcified lesions before stenting remains poorly studied. This study sought to compare the performance of up-front rotational atherectomy (RA) or balloon-based techniques before drug-eluting stent implantation in severely calcified coronary lesions as assessed by angiography and optical coherence tomography (OCT). Patient-level data from the PREPARE-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) and ISAR-CALC (Comparison of Strategies to Prepare Severely Calcified Coronary Lesions) randomized trials were pooled. The primary endpoint was stent expansion as assessed by OCT imaging. The secondary endpoints included stent eccentricity, stent asymmetry, angiographic acute lumen gain, strategy success and in-hospital occurrence of cardiac death, target vessel myocardial infarction, and repeat revascularization. Among 274 patients originally randomized, 200 participants with available OCT data after lesion preparation with RA (n = 63), a modified balloon (MB, n = 103), or a super high-pressure balloon (n = 34) before stenting were analyzed. The use of RA versus MB or a super high-pressure balloon led to comparable stent expansion (73.2% ± 11.6% vs 70.8% ± 13.6% vs 71.8% ± 12.2%, P = 0.49) and stent asymmetry (P = 0.83). Compared with RA or MB, a super high-pressure balloon was associated with less stent eccentricity (P = 0.03) with a numerically higher acute lumen gain, albeit not significantly different (P = 0.08). Strategy success was more frequent with RA versus MB (P = 0.002) and numerically more frequent with RA versus a super high-pressure balloon (P = 0.06). Clinical outcomes did not differ between groups. In patients with severely calcified lesions undergoing drug-eluting stent implantation, lesion preparation with RA, MB, or a super high-pressure balloon was associated with comparable stent expansion. A super high-pressure balloon is associated with less stent eccentricity, whereas strategy success is more frequent with RA. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
- Author
-
Lahu, Shqipdona, Behnes, Michael, Ndrepepa, Gjin, Neumann, Franz-Josef, Sibbing, Dirk, Bernlochner, Isabell, Menichelli, Maurizio, Mayer, Katharina, Richardt, Gert, Gewalt, Senta, Angiolillo, Dominick J., Coughlan, John Joseph, Aytekin, Alp, Witzenbichler, Bernhard, Hochholzer, Willibald, Cassese, Salvatore, Kufner, Sebastian, Xhepa, Erion, Sager, Hendrik B., and Joner, Michael
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
9. Reply: Targeting Inflammation and Immunology: A Hope for the Frequent Flyers?
- Author
-
Lenz, Tobias, Koch, Tobias, and Kufner, Sebastian
- Published
- 2024
- Full Text
- View/download PDF
10. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
- Author
-
Wöhrle, Jochen, Seeger, Julia, Lahu, Shqipdona, Mayer, Katharina, Bernlochner, Isabell, Gewalt, Senta, Menichelli, Maurizio, Witzenbichler, Bernhard, Hochholzer, Willibald, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J., Hemetsberger, Rayyan, Valina, Christian, Kufner, Sebastian, Xhepa, Erion, Hapfelmeier, Alexander, Sager, Hendrik B., Joner, Michael, and Richardt, Gert
- Abstract
The aim of this study was to assess the safety and efficacy of ticagrelor versus prasugrel for patients with acute coronary syndrome (ACS) according to their estimated glomerular filtration rates (eGFRs). The outcomes of ticagrelor versus prasugrel in patients with ACS according to eGFR have not been defined. Patients (n = 4,012) were categorized into 3 groups: low eGFR (<60 mL/min/1.73 m
2 ), intermediate eGFR (≥60 and <90 mL/min/1.73 m2 ), and high eGFR (≥90 mL/min/1.73 m2 ). The primary endpoint was a composite of all-cause death, myocardial infarction, and stroke; the secondary safety endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding, both at 1 year. Patients with low eGFRs had a higher risk for the primary endpoint compared with patients with intermediate eGFRs (adjusted HR: 1.89; 95% CI: 1.46-2.46]) and those with high eGFRs (adjusted HR: 2.33; 95% CI: 1.57-3.46). A risk excess for low eGFR was also observed for bleeding (adjusted HR: 1.55 [95% CI: 1.12-2.13] vs intermediate eGFR; adjusted HR: 1.59 [95% CI: 1.01-2.50] vs high eGFR). However, eGFR did not affect the relative efficacy and safety of ticagrelor versus prasugrel. In patients with low eGFR, the primary endpoint occurred in 20.5% with ticagrelor and in 14.7% with prasugrel (HR: 1.47; 95% CI: 1.04-2.08; P = 0.029); there was no significant difference in bleeding. These results show that among patients with ACS, reduction of eGFR is associated with increased risk for ischemic and bleeding events but has no significant impact on the relative efficacy and safety of ticagrelor versus prasugrel. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome [ISAR-REACT 5]; NCT01944800) [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents.
- Author
-
Kufner, Sebastian, Ernst, Maximilian, Cassese, Salvatore, Joner, Michael, Mayer, Katharina, Colleran, Roisin, Koppara, Tobias, Xhepa, Erion, Koch, Tobias, Wiebe, Jens, Ibrahim, Tareq, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, Byrne, Robert A, and ISAR-TEST-5 Investigators
- Subjects
- *
CORONARY artery surgery , *PROSTHETICS , *RESEARCH , *RAPAMYCIN , *DRUG-eluting stents , *RESEARCH methodology , *RETROSPECTIVE studies , *EVALUATION research , *MEDICAL cooperation , *CORONARY angiography , *TREATMENT effectiveness , *COMPARATIVE studies , *CORONARY artery disease , *FORECASTING , *POLYMERS , *CORONARY arteries , *LONGITUDINAL method , *PHARMACODYNAMICS - Abstract
Background: Outcome data after extended long-term follow-up of patients with coronary artery disease treated with drug-eluting stents (DES) in randomized clinical trials are scant.Objectives: Performance differences among devices may be expected to emerge over time depending on whether stenting is done with polymer-free or durable polymer DES. This study assessed the 10-year outcomes of patients enrolled in the ISAR-TEST-5 (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents) trial.Methods: A total of 3,002 patients were randomized to treatment with either polymer-free sirolimus- and probucol-eluting stents (n = 2,002) or durable polymer zotarolimus-eluting stents (n = 1,000). The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization (a device-oriented composite endpoint [DOCE]). Additional endpoints of interest were the patient-oriented composite endpoint (POCE), including all-cause death, any myocardial infarction, or any revascularization; individual components of the composite endpoints; and definite or probable stent thrombosis.Results: The median age of the patients at randomization was 67.8 years. At 10 years, 63.9% of patients were alive. The rates of DOCE and POCE were high in both groups with no difference in the incidence between polymer-free sirolimus- and probucol-eluting stents and durable polymer zotarolimus-eluting stents (DOCE: 43.8% vs. 43.0%, respectively; hazard ratio: 1.01; 95% confidence interval [CI]: 0.89 to 1.14; p = 0.90; POCE: 66.2% vs. 67.7%, respectively; hazard ratio: 0.94; 95% CI: 0.86 to 1.04; p = 0.22). The rates of the individual components of the composite endpoints were comparable in both groups. The incidence of definite/probable stent thrombosis over 10 years was low and comparable in both groups (1.6% vs. 1.9%; hazard ratio: 0.85; 95% CI: 0.46 to 1.54; p = 0.58).Conclusions: At 10 years, there were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES. The incidence of stent thrombosis was low and comparable in both groups. High overall adverse clinical event rates were observed during extended follow-up. (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents [ISAR-TEST-5]; NCT00598533). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?
- Author
-
Harada, Yukinori, Schneider, Simon, Colleran, Roisin, Rai, Himanshu, Bohner, Janika, Kuna, Constantin, Kufner, Sebastian, Giacoppo, Daniele, Schüpke, Stefanie, Joner, Michael, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
13. Progress in Drug-Eluting Stent Technology: Have We Come to the End of the Road?
- Author
-
Kastrati, Adnan and Kufner, Sebastian
- Published
- 2019
- Full Text
- View/download PDF
14. Sex differences in the outcome after percutaneous coronary intervention - A propensity matching analysis.
- Author
-
Ndrepepa, Gjin, Kufner, Sebastian, Mayer, Katharina, Cassese, Salvatore, Xhepa, Erion, Fusaro, Massimiliano, Hasimi, Endri, Schüpke, Stefanie, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Subjects
- *
PERCUTANEOUS coronary intervention , *CORONARY disease , *GENDER , *MYOCARDIAL infarction - Abstract
Background: Whether there are sex differences in the outcome of patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) remains controversial. We undertook this study to assess whether there are sex-related differences in the long-term mortality in a large series of patients with CAD after PCI.Methods: The study included 18,334 patients (4735 women and 13,599 men) with CAD treated with PCI. Propensity matching was performed to obtain a group of patients (3000 women and 3000 men) matched for all characteristics available in database. The primary outcome was a composite of cardiac mortality, myocardial infarction or stroke at 3 years of follow-up.Results: The primary outcome occurred in 660 women and 1440 men (Kaplan-Meier [KM] estimates, 15.2% in women and 11.6% in men, unadjusted hazard ratio [HR] = 1.35, 95% confidence interval [CI] 1.24 to 1.49; P < 0.001). Women were at higher risk of all-cause mortality (15.4% vs. 12.3%; P < 0.001), cardiac mortality (10.2% vs. 7.6%; P < 0.001) and stroke (2.6% vs. 1.4%; P < 0.001) than men. In matched patients, the primary outcome occurred in 371 women and 322 men (KM estimates, 13.4% vs. 11.6%, HR = 1.18 [1.01-1.36], P = 0.033). Women were at higher risk of myocardial infarction (4.2% vs. 3.1%; P = 0.044) but not cardiac (8.7% vs. 8.2%; P = 0.306) or all-cause death (12.5% vs. 12.9%; P = 0.991) or stroke (1.9% vs. 1.6%; P = 0.550) than men.Conclusions: After propensity matching, women remained at a higher risk of a composite of cardiac mortality, myocardial infarction or stroke up to 3 years after PCI than men. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction.
- Author
-
Ndrepepa, Gjin, Kufner, Sebastian, Hoyos, Magdalena, Harada, Yukinori, Xhepa, Erion, Hieber, Julia, Cassese, Salvatore, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Abstract
Background Evidence on the use of high-sensitivity cardiac troponins (hs-cTn) to risk-stratify patients with ST-segment elevation myocardial infarction (STEMI) is limited. Methods We assessed the prognostic value of preprocedural (admission) and peak postprocedural hs-cTnT in 818 patients with STEMI treated with primary percutaneous coronary intervention (PPCI). Preprocedural and peak postprocedural hs-cTnT was measured. The primary outcome was 3-year all-cause mortality. Results The median values of preprocedural and peak postprocedural hs-cTnT were 153 ng/L and 1980 ng/L. Overall, 134 patients died during the follow-up. There were 85 deaths in patients with preprocedural hs-cTnT >median value and 49 deaths in patients with preprocedural hs-cTnT ≤median value [Kaplan–Meier estimates of mortality, 22.2% and 13.5%; unadjusted hazard ratio (HR) = 1.88, 95% confidence interval (CI) 1.32–2.67, p < 0.001]. According to peak postprocedural hs-cTnT, there were 84 deaths in patients with postprocedural hs-cTnT >median value and 50 deaths in patients with postprocedural hs-cTnT ≤median value [Kaplan–Meier estimates of mortality, 22.3% and 13.4%; unadjusted HR = 1.82 (1.28–2.59), p < 0.001]. After adjustment, preprocedural [adjusted HR = 1.08 (1.03–1.12), p < 0.001] and peak postprocedural hs-cTnT value [adjusted HR = 1.06 (1.04–1.08), p < 0.001] were independently associated with 3-year mortality (with risk estimates calculated per 70 × 99th upper reference limit of hs-cTnT). The C statistic of multivariable model increased from 0.868 (0.841–0.895) to 0.872 (0.845–0.898) after incorporation of preprocedural hs-cTnT ( p = 0.050) and to 0.874 (0.846–0.899) after incorporation of the postprocedural hs-cTnT into the model ( p = 0.035). Conclusions In conclusion, admission or peak postprocedural hs-cTnT is independently associated with the risk for 3-year mortality in patients with STEMI undergoing PPCI. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions.
- Author
-
Colleran, Roisin, Kufner, Sebastian, Mehilli, Julinda, Rosenbeiger, Christian, Schüpke, Stefanie, Hoppmann, Petra, Joner, Michael, Mankerious, Nader, Fusaro, Massimiliano, Cassese, Salvatore, Abdel-Wahab, Mohamed, Neumann, Franz-Josef, Richardt, Gert, Ibrahim, Tareq, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan, Byrne, Robert A., and ISAR-CABG Investigators
- Subjects
- *
DRUG-eluting stents , *SAPHENOUS vein , *HEALTH outcome assessment , *DISEASE incidence , *CLINICAL trials , *SURGERY - Abstract
Background: In the ISAR-CABG (Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts?) trial, clinical outcomes at 1 year in patients undergoing treatment of saphenous vein graft lesions were superior with drug-eluting stents (DES) versus bare-metal stents.Objectives: The authors compared outcomes between treatment groups at 5 years.Methods: Patients were randomized (1:1:1:3) to receive DES (either permanent-polymer paclitaxel-eluting stents, permanent-polymer sirolimus-eluting stents, or biodegradable-polymer sirolimus-eluting stents) or bare-metal stents. The primary endpoint was the combined incidence of death, myocardial infarction (MI), or target lesion revascularization (TLR). Secondary endpoints were the composite of death or MI and TLR.Results: A total of 610 patients were allocated to treatment with DES (n = 303) or bare-metal stents (n = 307). At 5 years, the primary endpoint occurred in 159 (55.5%) versus 157 (53.6%) patients in the DES and bare-metal stent groups, respectively (hazard ratio [HR]: 0.98; 95% confidence interval [CI]: 0.79 to 1.23; p = 0.89). There was interaction between treatment effect and time (pinteraction = 0.005), with a lower event rate in the DES group at 1 year (HR: 0.64; 95% CI: 0.44 to 0.94; p = 0.02) but a numerically higher rate between 1 and 5 years (HR: 1.24; 95% CI: 0.94 to 1.63; p = 0.13). Death or MI occurred in 93 (32.8%) versus 108 (36.6%) patients, respectively (HR: 0.85; 95% CI: 0.64 to 1.12; p = 0.24), without significant interaction between treatment effect and time (pinteraction = 0.57). TLR occurred in 84 (33.1%) versus 69 (25.5%) patients in the DES and bare-metal stent groups, respectively (HR: 1.20; 95% CI: 0.87 to 1.64; p = 0.27). There was interaction between treatment effect and time (pinteraction <0.001): TLR was significantly lower in the DES group at 1 year (HR: 0.49; 95% CI: 0.28 to 0.86; p = 0.01) but significantly higher thereafter (HR: 2.02; 95% CI: 1.32 to 3.08; p = 0.001).Conclusions: In patients undergoing treatment of saphenous vein graft lesions, the advantage of DES over bare-metal stents demonstrated at 1 year was lost at 5 years due to higher attrition of efficacy in the DES group. (Efficacy Study of Drug-Eluting and Bare Metal Stents in Bypass Graft Lesions [ISAR-CABG]; NCT00611910). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
- Author
-
Kufner, Sebastian, Joner, Michael, Schneider, Simon, Tölg, Ralph, Zrenner, Bernhard, Repp, Janika, Starkmann, Alissa, Xhepa, Erion, Ibrahim, Tareq, Cassese, Salvatore, Fusaro, Massimiliano, Ott, Ilka, Hengstenberg, Christian, Schunkert, Heribert, Abdel-Wahab, Mohamed, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.
- Abstract
Objectives The aim of this study was to compare neointimal modification with scoring balloon pre-dilation before drug-coated balloon (DCB) versus DCB standard therapy in patients presenting with drug-eluting stent (DES) restenosis. Background DCB angioplasty for the treatment of coronary drug-eluting stent restenosis has demonstrated encouraging results. The efficacy of DCB treatment relies on rapid initial drug transfer and tissue retention of the antiproliferative drug. Neointimal modification with scoring balloon pre-dilation may enhance the efficacy of DCB therapy. Methods In this randomized, open-label, active-controlled trial, 252 patients with clinically significant DES restenosis were enrolled at 4 centers in Germany. Patients undergoing DCB angioplasty were randomly assigned to treatment with scoring balloon pre-dilation or standard therapy. The primary endpoint of the study was in-segment percentage diameter stenosis on 6- to 8-month follow-up angiography. The secondary endpoints included binary angiographic restenosis and late lumen loss on follow-up angiography, the combined incidence of death or myocardial infarction, target lesion revascularization, and target lesion thrombosis at 1 year. Results Follow-up angiographic data at 6 to 8 months were available for 203 patients (80.6%). Scoring balloon pre-dilation compared with standard therapy showed significantly lower rates with respect to the primary endpoint (35.0 ± 16.8% vs. 40.4 ± 21.4%; p = 0.047) and binary angiographic restenosis (18.5% vs. 32.0%; p = 0.026). Late lumen loss was numerically lower after scoring balloon pre-dilation compared with standard therapy (0.31 ± 59 mm vs. 0.41 ± 0.74 mm; p = 0.27). There was no difference between the groups in the incidence of death or myocardial infarction (4.0% vs. 3.4%; p = 0.73). Scoring balloon versus standard therapy showed comparable rates of target lesion revascularization (16.2% vs. 21.8%; p = 0.26). No target lesion thrombosis occurred out to 1 year. Conclusions In patients presenting with drug-eluting stent restenosis, neointimal modification with scoring balloon improves the antirestenotic efficacy of DCB therapy. (Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 [ISAR-DESIRE 4]; NCT01632371 ) [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
- Author
-
Wiebe, Jens, Hoppmann, Petra, Colleran, Roisin, Kufner, Sebastian, Valeskini, Michael, Cassese, Salvatore, Schneider, Simon, Joner, Michael, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.
- Abstract
Objectives The aim of this study was to report clinical outcomes in patients treated in routine practice 2 years after everolimus-eluting bioresorbable stent (BRS) implantation. Background Long-term results in patients undergoing BRS implantation in routine clinical practice are sparse, and existing evidence from randomized trials considers mostly selected patients. Methods The ISAR-ABSORB registry enrolled consecutive patients undergoing BRS implantation in routine clinical practice at 2 high-volume centers in Germany. Angiographic follow-up was scheduled after 6 to 8 months and clinical follow-up to 24 months. The primary endpoint was the composite of death, myocardial infarction, or target lesion revascularization, and secondary endpoints included individual components of the primary endpoint and definite stent thrombosis. Event rates were calculated using the Kaplan-Meier method. Results A total of 419 patients were included. The mean age was 66.6 ± 10.9 years, 31.5% had diabetes, and 39.0% presented with acute coronary syndrome. Forty-nine percent of lesions were considered complex (American College of Cardiology/American Heart Association type B2 or C), and 13.1% were bifurcation lesions. The mean reference vessel diameter was 2.89 ± 0.46 mm. At 2 years, the primary endpoint had occurred in 21.6% of patients: death in 6.3%, myocardial infarction in 3.9%, target lesion revascularization in 16.0%, and definite stent thrombosis in 3.8%. Conclusions Long-term follow-up of patients treated with BRS in routine practice showed higher event rates than expected. Future studies are required to determine the impact of changes in implantation technique and to define the optimal duration of dual antiplatelet therapy in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
- Author
-
Ndrepepa, Gjin, Iijima, Raisuke, Kufner, Sebastian, Braun, Siegmund, Cassese, Salvatore, Byrne, Robert A., Sorges, Jonas, Schulz-Schüpke, Stefanie, Hoppmann, Petra, Fussaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Abstract
Background: The association between coronary atherosclerosis progression or regression and long-term prognosis remains poorly defined. We assessed the association of atherosclerosis progression or regression with long-term mortality and factors that promote angiographic progression or regression of coronary atherosclerosis in patients with angiographically proven coronary artery disease.Methods: The study included 605 patients with coronary artery disease who underwent coronary angiography at baseline and at 2 years later. Pan-coronary artery tree quantitative coronary angiography was performed. Of 6259 coronary segments (10.3 lesions per patient) analyzed, 1790 non-stented segments with ≥25% diameter stenosis at baseline were included. Atherosclerosis progression or regression was defined as a decrease or increase in the mean minimal lumen diameter (MLD) of the non-stented segments of ≥0.2 mm in the 2-year angiography compared to baseline angiography. The primary outcome was all-cause mortality.Results: Based on the change in mean MLD between baseline and 2-year angiography, patients were divided into 3 groups: the group with progression of atherosclerosis (n=53; 8.8%), the group with no progression or regression of atherosclerosis (n=472; 78.0%) and the group with regression of atherosclerosis (n=80; 13.2%). There were 126 deaths over 8-year follow-up: 17 deaths among patients with progression, 103 deaths among patients with no progression/regression and 6 deaths among patients with regression (Kaplan-Meier estimates of mortality, 37.5%, 25.2% and 8.9%, respectively; adjusted hazard ratio=1.16, 95% confidence interval 1.05 to 1.29, P=.004 for 0.1 mm reduction in mean MLD).Conclusions: Progression or regression of coronary atherosclerosis in non-treated coronary segments was significantly associated with 8-year mortality. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
20. Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries: A Meta-Analysis of Randomized Trials.
- Author
-
Cassese, Salvatore, Ndrepepa, Gjin, Liistro, Francesco, Fanelli, Fabrizio, Kufner, Sebastian, Ott, Ilka, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, and Fusaro, Massimiliano
- Abstract
Objectives The aim of this study was to perform a meta-analysis of randomized trials investigating the outcomes of patients undergoing percutaneous revascularization with drug-coated balloons (DCBs) for atherosclerotic disease of the infrapopliteal arteries. Background The role of DCBs as revascularization therapy for infrapopliteal arteries represents a matter of ongoing controversy. Methods Scientific databases were searched for randomized trials of DCB therapy for atherosclerotic disease of the infrapopliteal arteries. The primary efficacy and safety outcomes were target lesion revascularization and amputation, respectively. Secondary outcomes were death, major adverse events, Rutherford class 5 or 6, and late lumen loss. Results A total of 641 patients enrolled in 5 trials received DCBs (n = 378) or control therapy (uncoated balloons or drug-eluting stents; n = 263). Median follow-up duration was 12 months. Patients treated with DCBs had risk for target lesion revascularization (risk ratio: 0.71; 95% confidence interval [CI]: 0.47 to 1.09; p = 0.12), amputation (risk ratio: 1.01; 95% CI: 0.65 to 1.58; p = 0.95), death (risk ratio: 1.14; 95% CI: 0.71 to 1.82; p = 0.59), major adverse events (risk ratio: 0.92; 95% CI: 0.59 to 1.43; p = 0.70), and Rutherford class 5 or 6 (risk ratio: 0.87; 95% CI: 0.46 to 1.62; p = 0.65) comparable with that of patients treated with control therapy. Lesions treated with DCBs showed lower late lumen loss (weighted mean difference −0.41; 95% CI: −0.79 to −0.03; p = 0.04) compared with those treated with control therapy. Conclusions In comparison with uncoated balloons or drug-eluting stents, the treatment of infrapopliteal arteries with DCBs is associated with similar clinical outcomes and favorable angiographic efficacy at 1-year follow-up. Further studies in larger numbers of patients are still needed to definitively address the role of DCB technology in this setting. (Drug-coated balloon for revascularization of tibialpedal arteries: a meta-analysis of randomized trials; CRD42015029283 ) [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
- Author
-
Kufner, Sebastian, Sorges, Jonas, Mehilli, Julinda, Cassese, Salvatore, Repp, Janika, Wiebe, Jens, Lohaus, Raphaela, Lahmann, Annalena, Rheude, Tobias, Ibrahim, Tareq, Massberg, Steffen, Laugwitz, Karl L., Kastrati, Adnan, and Byrne, Robert A.
- Abstract
Objectives The aim of this study was to evaluate the late clinical performance of a polymer-free sirolimus- and probucol-eluting stent compared with a new-generation durable polymer-based zotarolimus-eluting stent. Background It was previously shown that polymer-free sirolimus- and probucol-eluting stents were noninferior to zotarolimus-eluting stents at 12 months. However, long-term follow-up of these devices is critical to evaluate late comparative efficacy. Methods In a clinical trial with minimal exclusion criteria, 3,002 patients were randomly assigned to treatment with polymer-free sirolimus- and probucol-eluting stents versus zotarolimus-eluting stents. The primary endpoint was the combined incidence of cardiac death, target vessel–related myocardial infarction, or target lesion revascularization. Results At 5 years, there was no difference in the incidence of the primary endpoint between sirolimus- and probucol-eluting stents and zotarolimus-eluting stents (23.8% vs. 24.2%, respectively; hazard ratio: 0.98; 95% confidence interval: 0.84 to 1.15; p = 0.80). The rates of the individual components of the primary endpoint were also comparable in both groups. The incidence of definite or probable stent thrombosis was low in both groups (1.3% vs. 1.6%, respectively; hazard ratio: 0.86; 95% confidence interval: 0.46 to 1.62; p = 0.64). The rates of any death, myocardial infarction, and revascularization were similar in both groups. Results were consistent across pre-specified subgroups of age, sex, diabetes, and vessel size. Conclusions Long-term outcomes of patients treated with polymer-free sirolimus- and probucol-eluting stents compared with a new-generation durable polymer-based zotarolimus-eluting stent were similar. Rates of stent thrombosis were low and comparable in both treatment groups, with few events beyond 12 months. (Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis [ISAR-TEST-5]; NCT00598533 ) [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
- Author
-
Kufner, Sebastian, Cassese, Salvatore, Valeskini, Marco, Neumann, Franz-Josef, Schulz-Schüpke, Stefanie, Hoppmann, Petra, Fusaro, Massimiliano, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.
- Abstract
Objectives This study sought to investigate the long-term comparative efficacy and safety of paclitaxel-eluting balloon (PEB), paclitaxel-eluting stent (PES), or balloon angioplasty (BA) for the treatment of drug-eluting stent restenosis. Background The optimal treatment of drug-eluting stent restenosis remains unknown. Although PEB has shown encouraging results, the long-term clinical efficacy and safety of PEB remains poorly defined. Methods A total of 402 patients with clinically significant restenosis in limus-eluting stents were randomly assigned to receive PEB (n = 137), PES (n = 131), or BA (n = 134). For this analysis, PEB versus PES and PEB versus BA were compared. The primary efficacy and safety endpoints were target lesion revascularization and the composite of death or myocardial infarction. Results At a median follow-up of 3 years, the risk of target lesion revascularization was comparable with PEB versus PES (hazard ratio [HR]: 1.46, 95% confidence interval [CI]: 0.91 to 2.33; p = 0.11) and lower with PEB versus BA (HR: 0.51, 95% CI: 0.34 to 0.74; p < 0.001). The risk of death/myocardial infarction tended to be lower with PEB versus PES (HR: 0.55, 95% CI: 0.28 to 1.07; p = 0.08), due to a lower risk of death (HR: 0.38, 95% CI: 0.17 to 0.87; p = 0.02). The risk of death/myocardial infarction was similar with PEB versus BA (HR: 0.96, 95% CI: 0.46 to 2.0; p = 0.91). Conclusions At 3 years, the use of PEB as compared with PES to treat patients with limus-eluting stent restenosis has similar efficacy and safety. PEB remains superior to BA. The sustained efficacy without trade-off in safety supports the role of PEB as treatment option for patients with drug-eluting stent restenosis. (Intracoronary Stenting and Angiographic Results: Drug Eluting Stent In-Stent Restenosis: 3 Treatment Approaches [ISAR-DESIRE 3]; NCT00987324 ) [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries.
- Author
-
Kufner, Sebastian, Cassese, Salvatore, Groha, Philipp, Byrne, Robert A., Schunkert, Heribert, Kastrati, Adnan, Ott, Ilka, and Fusaro, Massimiliano
- Subjects
- *
ENDOVASCULAR surgery , *ILIAC artery , *IATROGENIC diseases , *FEMORAL artery , *TRANSLUMINAL angioplasty , *HEALTH outcome assessment , *WOUNDS & injuries - Abstract
Background The growing number of complex endovascular procedures is expected to increase the risk of iatrogenic injuries of peripheral arteries. A strategy of percutaneous transluminal angioplasty (PTA) with covered stent (CS) may represent a valuable alternative to open surgery. However, systematic evaluations of CS in this setting represent a scientific gap. In the present study, we investigate the procedural and clinical outcomes associated with PTA and CS implantation to repair iatrogenic injuries of peripheral arteries. Methods All patients undergoing PTA with CS for endovascular repair of iatrogenic injuries of peripheral arteries between August 2010 and July 2013 at our Institution were retrospectively analyzed. The primary endpoint was the technical success. Secondary endpoints were in-hospital mortality and cumulative death, target lesion revascularization (TLR), amputation and major stroke at 12-month follow-up. Results During the period of observation, a total of 30 patients underwent PTA with either self-expandable (43.3%) or balloon-expandable CS (56.7%) for iatrogenic injuries of peripheral arteries. Injuries consisted of perforation/rupture (76.7%), arteriovenous fistula (16.7%) and pseudoaneurysm (6.7%) of iliac–femoral arteries. Technical success was achieved in all cases. Median follow-up was 409 days [210–907]. The incidence of in-hospital mortality was 10.0%. At 12-month follow-up, the incidence of death, TLR, amputation and major stroke was 20.0%, 17.0%, 3.3% and 6.7%, respectively. Conclusion The use of covered stents for endovascular repair of iatrogenic injuries of peripheral arteries shows a high technical success and may be alternative to surgery. Further studies with larger populations are needed to confirm these preliminary findings. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial.
- Author
-
Kufner, Sebastian, Byrne, Robert A., de Waha, Antoinette, Schulz, Stefanie, Joner, Michael, Laugwitz, Karl-Ludwig, and Kastrati, Adnan
- Subjects
- *
RAPAMYCIN , *PACLITAXEL , *SURGICAL stents , *PEOPLE with diabetes , *CORONARY restenosis , *MYOCARDIAL infarction - Abstract
Background: Concern exists relating to potential attenuated efficacy of limus-eluting stents in patients with diabetes mellitus. In this respect diabetic patients with sirolimus-eluting stent (SES) failure requiring reintervention may be expected to derive particular benefit from a treatment-switch to paclitaxel-eluting stent (PES) implantation. Objective: The aim of the current report was to investigate outcomes of patients with SES restenosis randomized to treatment with SES (same stent strategy) or PES (switch stent strategy) in the pre-specified subgroups of patients with and without diabetes mellitus. Methods: In the setting of ISAR-DESIRE 2 trial, 450 patients with clinically significant SES restenosis were randomly assigned to receive either SES or PES. The primary end point was in-stent late loss at 6–8month follow-up angiography. Secondary endpoints were binary angiographic restenosis (diameter stenosis >50%) and target lesion revascularization (TLR), the composite of death or myocardial infarction (MI) and definite stent thrombosis at 12months. Results: Of 450 patients enrolled, 162 (36.0%) had a diagnosis of diabetes mellitus. In patients with diabetes 86 patients were randomly assigned to SES versus 76 to PES. In patients without diabetes 139 were assigned to SES versus 149 to PES. Late loss was comparable between SES and PES both in patients with diabetes (0.38±0.59mm vs. 0.37±0.59mm; p=0.97) and without (0.41±0.67mm vs. 0.38±0.6mm; p=0.98; pinteraction =0.89). Similarly binary restenosis was comparable between SES and PES in patients with diabetes (19.0% vs. 26.0%; p=0.32) or without (18.9% vs. 17.8%; p=0.98; pinteraction =0.36). TLR, death or MI and definite stent thrombosis were also similar in SES versus PES treatment groups regardless of diabetes status. Conclusions: In cases of SES-restenosis, treatment with either repeat SES or switch to PES was associated with a comparable degree of efficacy, regardless of diabetic status. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease.
- Author
-
Kufner, Sebastian, de Waha, Antoinette, Tomai, Fabrizio, Park, Seong-Wook, Lee, Seung-Whan, Lim, Do-Sun, Kim, Moo Hyun, Galloe, Anders M., Maeng, Michael, Briguori, Carlo, Dibra, Alban, Schömig, Albert, and Kastrati, Adnan
- Abstract
Background: There is an ongoing debate on the optimal drug-eluting stent (DES) in diabetic patients with coronary artery disease. We addressed this issue by making a synthesis of the available evidence on the relative long-term efficacy and safety of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) in these patients. Methods: Individual patient data were analyzed from 6 randomized trials specifically designed to compare SES with PES in diabetic patients. In total, 1183 patients were followed up for a median of 3.9 years (25th, 75th percentiles 3.4-4.5 years). The primary efficacy end point was target lesion revascularization (TLR). The composite of death and myocardial infarction (MI) was the primary safety end point. Stent thrombosis was a secondary end point. Overall hazard ratios (HRs) with 95% CIs were calculated as summary estimates. Results: No significant heterogeneity was seen across the 6 randomized trials for all analyzed events. Sirolimus-eluting stent was associated with a significant reduction in the risk of TLR (HR 0.65 [0.47-0.91], P = .01). No significant differences were observed regarding the risk of death or MI (HR 1.04 [0.74-1.45], P = .83) and stent thrombosis (HR 1.00 [0.31-3.30], P = .67). Mortality was also not affected by the type of DES (HR 0.95 [0.65-1.39], P = .79). Conclusions: In diabetic patients with coronary artery disease, SES leads to a sustained reduction in the risk of TLR compared with PES. Both these DES types are, however, comparable with respect to the risk of stent thrombosis, MI, or death over long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
26. Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention.
- Author
-
Ndrepepa, Gjin, Mehilli, Julinda, Tiroch, Klaus, Fusaro, Massimiliano, Kufner, Sebastian, Ellert, Julia, Goedel, Julia, Schömig, Albert, and Kastrati, Adnan
- Subjects
MYOCARDIAL infarction ,CARDIAC surgery ,MYOCARDIAL infarction-related mortality ,CORONARY circulation ,ANGIOPLASTY ,THROMBOLYTIC therapy ,HEALTH outcome assessment ,PROPORTIONAL hazards models - Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
27. Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis.
- Author
-
Kufner, Sebastian, Hausleiter, Jörg, Ndrepepa, Gjin, Schulz, Stefanie, Bruskina, Olga, Byrne, Robert A., Fusaro, Massimiliano, Kastrati, Adnan, Schömig, Albert, and Mehilli, Julinda
- Subjects
RAPAMYCIN ,CORONARY restenosis ,ANGIOPLASTY ,REVASCULARIZATION (Surgery) ,MYOCARDIAL infarction ,CORONARY disease - Abstract
Objectives: We sought to investigate the long-term efficacy of oral sirolimus therapy and its impact on the incidence of de novo malignancies in the OSIRIS (Oral Sirolimus to Inhibit Recurrent In-Stent Stenosis) trial population. Background: The OSIRIS trial showed a significant reduction of angiographic restenosis with an oral adjunctive sirolimus treatment for in-stent restenosis. The long-term efficacy of oral sirolimus therapy is unknown. Methods: Three hundred patients with in-stent restenosis were randomly assigned to receive placebo, a cumulative loading dose of 8 mg (usual-dose), or 24 mg (high-dose) of sirolimus over 3 days (2 days before and the day of intervention) followed by maintenance therapy of 2 mg/day for 7 days. The primary outcome of this analysis was the incidence of composite of death, myocardial infarction, and target vessel revascularization at 4-year follow-up. Secondary outcome was the incidence of newly diagnosed malignancies. Results: No significant differences were observed between placebo, usual-, and high-dose sirolimus treatment groups regarding primary outcome (33.3%, 39.4%, and 31.3%, respectively; p = 0.46), death (5.9%, 9.1%, and 11.1%, respectively; p = 0.41), target vessel revascularization (30.4%, 30.3%, and 22.2%, respectively; p = 0.33), and rate of newly diagnosed malignancies (7.8%, 3.0%, and 11.1%, respectively; p = 0.09). Conclusions: The benefit in the reduced need for repeat intervention observed at 1 year with high-dose oral sirolimus therapy was attenuated over 4 years. Moreover, this regimen was associated with numerical yet not a significant increase in newly diagnosed malignancies without augmenting the malignancy-induced risk of death. (Oral Sirolimus for In-Stent Restenosis [OSIRUS] trial; NCT00859183) [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
28. TCT-283 10-Year Clinical Outcomes From a Trial of 3 Limus-Eluting Stents With Different Polymer Coatings in Diabetic Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial.
- Author
-
Kufner, Sebastian, Lenz, Tobias, Joner, Michael, Cassese, Salvatore, Xhepa, Erion, Byrne, Robert, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, and Kastrati, Adnan
- Subjects
- *
CORONARY disease , *DRUG-eluting stents , *POLYMERS , *SURFACE coatings , *PEOPLE with diabetes - Published
- 2019
- Full Text
- View/download PDF
29. Clinical Safety and Efficacy of New-Generation Single-Layer Polytetrafluorethylene Covered Coronary Stents.
- Author
-
Voll, Felix, Koch, Tobias, Tölg, Ralph, Lenz, Tobias, Schroeter, Mira, Lenders, Guy, Hokken, Raymond, Cassese, Salvatore, Xhepa, Erion, Schunkert, Heribert, Kastrati, Adnan, and Kufner, Sebastian
- Subjects
- *
SURGICAL stents , *DRUG-eluting stents , *CORONARY artery bypass , *PERCUTANEOUS coronary intervention , *CORONARY arteries , *ANGIOGRAPHY - Abstract
Early-generation "sandwich-design" polytetrafluorethylene (PTFE) covered coronary stents (CS) are associated with a high frequency of adverse events. New-generation single layer PTFE-CS offers the potential to enhanced procedural efficacy and improves clinical safety. Data from a dedicated study, concerning outcomes after treatment with single-layer PTFE-CS in patients undergoing percutaneous coronary intervention are scant. This is a retrospective multicenter registry including 30 patients undergoing implantation of 39 single-layer PTFE-CS (BeGraft-coronary Stent Graft System, Bentley InnoMed GmbH, Hechingen, Germany) in native coronary arteries or saphenous bypass grafts, in 3 centers in Europe, between May 2013 and May 2019. Endpoints of interest were procedural success (placement of covered stent), binary-angiographic restenosis (BAR), percent diameter stenosis (% DS) and late-lumen loss at 6–8 months follow-up angiography, rates of target lesion revascularization (TLR), myocardial infarction (MI), stent thrombosis (ST) and mortality at 12 months. 28 patients underwent implantation of 37 CS due to coronary artery perforation 2 patients due to coronary artery aneurysm. Technical success was achieved in all patients (100 %). More than one stent was implanted in 7 patients (25 %) all in the perforation group. Follow-up angiography was available in 23 patients (77 %) showing favorable results: BAR = 21.8 %, %DS = 30.3 ± 27.5; LLL = 0.16 ± 0.81 mm. At 12 months all patients were alive, rates of TLR were low (3 patients, 10.0 %), there was one case of late stent thrombosis (3.3 %) and one MI (3.3 %). In this dedicated study, implantation of a new single layer PTFE-CS for the treatment of native coronary arteries or saphenous vein grafts after perforation or due to aneurysm showed high technical success rates and favorable angiographic and clinical efficacy. Clinical safety outcomes are encouraging, but larger prospective studies are needed to determine long-term safety of this device. • This is a multicenter registry including 30 patients undergoing PCI with implantation of 39 PTFE-CS in native coronary arteries or SVG due to perforation or aneurysm at 3 centers in Europe. • Procedural and postprocedural outcome at index PCI, angiographic FU at 6-8 months and clinical FU out to 12 months was obtained. • We observed high technical success rate (100%) at index PCI and favorable angiographic results in terms of binary angiographic restenosis, late lumen loss, % diameter stenosis and low clinical event rates at 12 months: TLR (10.0%), MI (3.3%) and ST (3.3%). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. FINAL FIVE-YEAR FOLLOW-UP OF POLYMER-FREE SIROLIMUS- AND PROBUCOL-ELUTING STENTS VERSUS NEW GENERATION ZOTAROLIMUS-ELUTING STENTS IN PATIENTS WITH CORONARY ARTERY DISEASE.
- Author
-
Byrne, Robert A., Kufner, Sebastian, Sorges, Jonas, Repp, Janika, Cassese, Salvatore, Schulz, Stefanie, Fusaro, Massimiliano, Ott, Ilka, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, and Kastrati, Adnan
- Subjects
- *
FOLLOW-up studies (Medicine) , *RAPAMYCIN , *CORONARY disease , *HEART diseases , *THERAPEUTICS , *SURGICAL stents , *HEART disease diagnosis - Published
- 2015
- Full Text
- View/download PDF
31. Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention.
- Author
-
Guerra, Elena, Ndrepepa, Gjin, Schulz, Stefanie, Byrne, Robert, Hoppmann, Petra, Kufner, Sebastian, Ibrahim, Tareq, Tada, Tomohisa, Schunkert, Heribert, Laugwitz, Karl-Ludwig, and Kastrati, Adnan
- Abstract
Background Inhospital stent thrombosis (ST) and cerebrovascular accidents (CVA) are rare but serious adverse events after percutaneous coronary intervention (PCI). The association of ST or CVA with long-term outcome after PCI remains poorly investigated. Methods The study included 18,334 consecutive patients who underwent PCI. Patients were divided into 3 groups: the group with ST, the group with CVA, and the group without these events. The primary outcome was all-cause mortality at 3-year follow-up. Results Inhospital ST or CVA occurred in 59 patients (0.32%) and in 90 patients (0. 49%), respectively. There were 2,149 deaths (11.7%) during the follow-up: 26 deaths among patients with ST, 32 deaths among patients with CVA, and 2,091 deaths among patients without ST or CVA (Kaplan-Meier estimates of 3-year mortality 45.3%, 38.0%, and 12.9%, odds ratio 6.1, 95% CI 3.6-10.2, P < .001 for ST group vs the group without ST or CVA and odds ratio 4.2 [2.7-6.6], P < .001 for CVA group vs the group without ST or CVA). There was no significant difference in the 3-year mortality between CVA and ST groups ( P = .29). The Cox proportional hazards model showed that ST (adjusted hazard ratio 4.97, 95% CI 2.58-9.56, P < .001) and CVA (adjusted hazard ratio 2.25 [1.25-4.04], P = .006) were independently associated with the increased risk of 3-year mortality. Conclusion Inhospital ST and CVA after PCI are associated with the increased risk of 3-year mortality. Both events seem to have a similar impact on long-term survival. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. COMPARATIVE ANTIRESTENOTIC EFFICACY OF BIODEGRADABLE POLYMER AND PERMANENT POLYMER DRUG-ELUTING STENTS: THE ANGIOGRAPHIC FOLLOW-UP RESULTS OF THE ISAR-TEST-4 RANDOMIZED TRIAL
- Author
-
Kufner, Sebastian F., Byrne, Robert A., Schulz, Stefanie, Birkmeier, Katrin A., Tiroch, Klaus, Pinieck, Susanne, Hurt, Silvia, Pache, Jürgen, Mehilli, Julinda, and Herzzentrum, Deutsches
- Published
- 2010
- Full Text
- View/download PDF
33. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
- Author
-
Mehilli, Julinda, Ndrepepa, Gjin, Kastrati, Adnan, Neumann, Franz-Josef, ten Berg, Jurriën, Bruskina, Olga, Dotzer, Franz, Seyfarth, Melchior, Pache, Jürgen, Kufner, Sebastian, Dirschinger, Josef, Berger, Peter B., and Schömig, Albert
- Subjects
CORONARY disease ,DIAGNOSIS ,CORONARY heart disease complications ,PERCUTANEOUS endoscopic gastrostomy ,FIBRINOLYTIC agents - Abstract
Background: It is not known whether there exists a sex-dependent difference in the clinical benefit of abciximab in patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI). Methods: We performed this retrospective analysis of 2022 patients (498 women) with ACS enrolled in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial and randomized to receive abciximab or placebo during a PCI procedure. The incidence of major adverse cardiac events (MACE) during the 30 days after PCI was the primary end point of the study. Results: Among men, the 30-day incidence of MACE was 8.6% in the abciximab group compared with 12.6% in the placebo group, relative risk (RR) 0.69 (95% confidence interval [CI] 0.50-0.94), P = .01. The 30-day incidence of MACE in women was 9.7% in the abciximab group compared with 9.9% in the placebo group, RR 0.98 (95% CI, 0.56-1.72), P = .97. After adjustment for baseline clinical and angiographic characteristics, there was no significant interaction between sex and abciximab (P = .71); adjusted RR was 0.70 (95% CI, 0.34-1.34) in women and 0.60 (95% CI, 0.40-0.90) in men. The incidence of major bleeding was significantly greater in women (3.6%) than in men (0.7%), RR 5.5 (95% CI, 2.54-11.9), P < .001, without any dependence on the form of therapy received. Conclusions: In patients with non-ST elevation ACS undergoing a PCI, the benefit with abciximab is greater in men than in women. This is apparently the result of sex-based differences in risk profile. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
34. Alkaline phosphatase and prognosis in patients with diabetes mellitus and ischemic heart disease.
- Author
-
Ndrepepa, Gjin, Holdenrieder, Stefan, Xhepa, Erion, Cassese, Salvatore, Lahu, Shqipdona, Kufner, Sebastian, and Kastrati, Adnan
- Subjects
- *
MYOCARDIAL ischemia , *CORONARY disease , *ALKALINE phosphatase , *PEOPLE with diabetes , *DIABETES - Abstract
• ALP predicts 3-year mortality in patients with diabetes mellitus and ischemic heart disease. • Low and high ALP activity levels were associated with increased risk of mortality. • Impaired renal function and elevated C-reactive protein correlated with higher ALP activity. The association between alkaline phosphatase (ALP) and mortality in patients with diabetes mellitus (DM) and ischemic heart disease (IHD) remains poorly investigated. The study included 1426 patients with DM and IHD who underwent percutaneous coronary intervention. Patients were divided in groups according to tertiles of ALP activity: a group with ALP activity in 1st tertile (ALP activity: 20.8–65.0 U/L; n = 478), a group with ALP activity in 2nd tertile (ALP activity: 65.1–87.0 U/L; n = 473) and a group with ALP activity in 3rd tertile (ALP activity: 87.1–1520 U/L; n = 475). The primary endpoint was 3-year all-cause mortality. At 3 years, all-cause deaths occurred in 182 patients: 50 deaths (12.4%) in patients of 1st tertile, 47 deaths (11.7%) in patients of 2nd tertile and 85 deaths (20.8%) in patients of 3rd tertile of ALP activity (adjusted hazard ratio [HR] = 1.20, 95% confidence interval [CI] 1.02 to 1.42, P = 0.031); cardiac deaths occurred in 110 patients: 28 deaths (7.0%) in patients of 1st tertile, 30 deaths (7.6%) in patients of 2nd tertile and 52 deaths (12.7%) in patients of 3rd tertile of ALP activity (adjusted HR = 1.27 [1.04–1.56], P = 0.021, with both risk estimates calculated for unit increment in the log scale of ALP activity). The C-statistic of the multivariable model with baseline data without and with ALP was 0.787 [0.750–0.818] and 0.804 [0.757–0.851], (P = 0.575) for all-cause mortality and 0.832 [0.798–0.864] and 0.876 [0.833–0.918], (P = 0.115) for cardiac mortality. In patients with DM and IHD, elevated ALP activity was associated with increased risk of 3-year mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy.
- Author
-
Hemetsberger, Rayyan, Richardt, Gert, Lahu, Shqipdona, Valina, Christian, Menichelli, Maurizio, Abdelghani, Mohammad, Wöhrle, Jochen, Toelg, Ralph, Witzenbichler, Bernhard, Mankerious, Nader, Liebetrau, Christoph, Bernlochner, Isabell, Hamm, Christian W., Allali, Abdelhakim, Joner, Michael, Fusaro, Massimiliano, Xhepa, Erion, Hapfelmeier, Alexander, Kufner, Sebastian, and Sager, Hendrik B.
- Subjects
- *
ACUTE coronary syndrome , *PRASUGREL , *TICAGRELOR , *TREATMENT effectiveness , *CORONARY angiography , *RESEARCH , *MEDICAL care , *MYOCARDIAL infarction , *EVALUATION research , *CARDIOVASCULAR system , *COMPARATIVE studies , *PLATELET aggregation inhibitors - Abstract
Background: Whether the access site influences the comparative efficacy and safety of ticagrelor and prasugrel in patients with acute coronary syndrome (ACS) undergoing invasive treatment strategy remains unstudied.Methods: This post-hoc analysis included ACS patients undergoing invasive treatment via radial or femoral access and randomized to either ticagrelor or prasugrel in the ISAR-REACT 5 trial. The primary efficacy endpoint was the composite of death, myocardial infarction (MI) or stroke, safety endpoint was BARC 3 to 5 bleeding. Outcomes were assessed out to 12 months after randomization.Results: Out of 4018 patients, 3984 underwent invasive treatment via radial or femoral access. 1479 had coronary angiography via radial access (ticagrelor, N = 748; prasugrel, N = 731) and 2505 via femoral access (ticagrelor, N = 1245; prasugrel, N = 1260). There was no interaction between access route and assignment to either ticagrelor or prasugrel regarding the primary efficacy or safety endpoints (P for interaction≥0.616). In the radial group, the primary efficacy endpoint (7.6% versus 5.8%, HR: 1.32 [0.88-1.97], P = 0.151) and the safety endpoint (4.3% versus 3.0%, HR: 1.36, [0.73-1.31], P = 0.300) were not statistically different in patients receiving either ticagrelor or prasugrel. In the femoral group, the primary efficacy endpoint occurred more frequently in patients assigned to ticagrelor as compared to prasugrel (10.3% versus 7.3%, HR: 1.44 [1.10-1.88], P = 0.006) without significant difference in terms of safety endpoint (6.4% versus 5.8%, HR: 1.14, [0.81-1.60], P = 0.470).Conclusions: In patients with ACS undergoing an invasive treatment strategy, the access route does not influence the comparative efficacy and safety of ticagrelor and prasugrel.Clinical Trial Registration: NCT01944800. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
- Author
-
Valina, Christian, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Aytekin, Alp, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J, Kufner, Sebastian, Liebetrau, Christoph, Hamm, Christian W, Xhepa, Erion, Hapfelmeier, Alexander, Sager, Hendrik B, Wustrow, Isabel, and Joner, Michael
- Subjects
- *
TREATMENT of acute coronary syndrome , *RESEARCH , *RESEARCH methodology , *NEUROTRANSMITTERS , *ACUTE coronary syndrome , *EVALUATION research , *MEDICAL cooperation , *CORONARY angiography , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PLATELET aggregation inhibitors , *DRUGS , *DISEASE complications - Abstract
Background: Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardial infarction (MI).Objectives: This study sought to investigate the benefits and risks of ticagrelor as compared with prasugrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) and planned invasive management.Methods: This post hoc analysis combines the pre-specified subgroups of UA and NSTEMI of the randomized ISAR-REACT 5 trial. It included 1,179 patients assigned to ticagrelor and 1,186 assigned to prasugrel. Ticagrelor was started immediately after randomization and prasugrel after coronary angiography. The primary endpoint was a composite of death, MI, or stroke during 1-year follow-up, and the safety endpoint was Bleeding Academic Research Consortium class 3-5.Results: The primary endpoint was reached in 101 (8.7%) patients in the ticagrelor and in 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.04 to 1.90). The HR for all-cause death was 1.43 (95% CI: 0.93 to 2.21) and that for MI 1.43 (95% CI: 0.94 to 2.19). The safety endpoint occurred in 49 (5.2%) patients in the ticagrelor and in 41 (4.7%) patients in the prasugrel group (HR: 1.09; 95% CI: 0.72 to 1.65). Landmark analysis revealed persistence of the efficacy advantage with prasugrel after the first month.Conclusions: In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor in reducing the combined 1-year risk of death, MI, and stroke without increasing the risk of bleeding. Due to the post hoc nature of the analysis, these findings need confirmation by further studies. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
37. Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography.
- Author
-
Hoppmann, Petra, Rai, Himanshu, Colleran, Roisin, Kufner, Sebastian, Wiebe, Jens, Cassese, Salvatore, Joner, Michael, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.
- Subjects
- *
OPTICAL coherence tomography , *ANGIOGRAPHY , *THROMBOSIS , *CORONARY angiography , *MEDICAL equipment , *PROSTHETICS , *RESEARCH , *PREDICTIVE tests , *TIME , *RESEARCH methodology , *MEDICAL care , *EVALUATION research , *MEDICAL cooperation , *CARDIOVASCULAR system , *CARDIOVASCULAR agents , *CORONARY thrombosis , *TREATMENT effectiveness , *COMPARATIVE studies , *CORONARY artery disease , *PLATELET aggregation inhibitors - Abstract
Purpose: Everolimus-eluting bioresorbable scaffolds (BRS) demonstrated an increased risk of very late scaffold thrombosis (VLScT) in comparison with conventional drug-eluting stents. However, characterization of VLScT cases remains scant and the role of interim angiographic surveillance in identifying patients at risk of VLScT is unclear. We therefore set out to identify angiographic predictors of VLScT in our present case series.Methods: We analyzed a series of consecutive patients with VLScT presenting to two centers in Munich, Germany. Of interest, all patients had undergone interim planned surveillance angiography. Angiographic films were collected and reviewed and quantitative coronary angiography analysis was done at a core laboratory. Optical coherence tomography (OCT) images at presentation with VLScT were analyzed in patients with available data.Results: Nine patients presented with 10 VLScT events. Mean age was 62.6 years. Surveillance angiography (between 159 and 476 days) were unremarkable in all cases. Time from index intervention to VLScT ranged from 393 to 1494 days. Nine of 10 events occurred after discontinuation of dual antiplatelet therapy. Four patients underwent OCT. The dominant finding at the time of VLScT was scaffold discontinuity.Conclusions: In a series of patients with VLScT after treatment with BRS, routine interim surveillance angiography was available in all patients and failed to identify features predictive of subsequent adverse events. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
38. Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention.
- Author
-
Harada, Yukinori, Koskinas, Konstantinos C., Ndrepepa, Gjin, Räber, Lorenz, Braun, Siegmund, Zanchin, Thomas, Kufner, Sebastian, Hunziker, Lukas, Byrne, Robert A., Heg, Dik, Kastrati, Adnan, and Windecker, Stephan
- Subjects
- *
TROPONIN , *MYOCARDIAL infarction , *MYOCARDIAL infarction treatment , *SENSITIVITY analysis , *PATIENTS , *PROGNOSIS - Abstract
Background: The association of postprocedural high-sensitivity troponin T (hs-TnT) with prognosis of non-ST-segment elevation myocardial infarction (NSTEMI) patients is incompletely investigated.Aim: To assess the prognostic value of hs-TnT in NSTEMI patients undergoing early percutaneous coronary intervention (PCI).Methods: This study included 3783 patients with NSTEMI undergoing early PCI. Preprocedural and peak postprocedural hs-TnT was measured. Patients were divided into 3 groups: a group with postprocedural hs-TnT in the 1st tertile (hs-TnT <105ng/L; n=1264), a group with postprocedural hs-TnT in the 2nd tertile (hs-TnT ≥105ng/L to 470ng/L; n=1258) and a group with postprocedural hs-TnT in the 3rd tertile (hs-TnT >470ng/L; n=1261). The primary outcome was 1-year all-cause mortality.Results: Overall, there were 299 deaths: 59 (5.5%), 98 (8.2%) and 142 deaths (12.6%) among patients of the 1st, 2nd and 3rd postprocedural hs-TnT tertiles (unadjusted hazard ratio [HR]=1.65, 95% confidence interval [CI] 1.20 to 2.67; P=0.002 for tertile 2 vs tertile 1 and unadjusted HR=2.41 [1.79-3.25]; P<0.001 for tertile 3 vs tertile 1). After adjustment postprocedural hs-TnT was independently associated with the risk of all-cause mortality (adjusted [HR]=1.22 [1.13-1.33], P<0.001 for 1 unit higher log hs-TnT). Postprocedural hs-TnT improved the risk prediction of the model of all-cause mortality (the C statistic of the model without [with baseline variables only] and with incorporation of postprocedural hs-TnT was 0.759 [0.732-0.782] and 0.772 [0.746-0.794], respectively; P<0.001).Conclusions: In patients with NSTEMI undergoing early PCI, postprocedural hs-TnT is independently associated with increased risk of mortality up to 1year after PCI. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
39. TCT-483 Angiographic and two-year clinical outcomes following percutaneous coronary intervention for in-stent restenosis of polymer-free sirolimus- and probucol-eluting stent compared with durable polymer zotarolimus-eluting stent.
- Author
-
Harada, Yukinori, Colleran, Roisin, Kufner, Sebastian, Giacoppo, Daniele, Rheude, Tobias, Michel, Jonathan, Wiebe, Jens, Cassese, Salvatore, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert
- Subjects
- *
CORONARY restenosis , *CORONARY angiography , *PERCUTANEOUS coronary intervention , *RAPAMYCIN , *MEDICAL polymers , *SURGICAL stents , *DRUG-eluting stents , *THERAPEUTICS - Published
- 2016
- Full Text
- View/download PDF
40. TCT-58 Long-term clinical outcomes of patients treated with everolimus-eluting bioresorbable scaffolds during daily practice - 2-year results from the ISAR-ABSORB Registry.
- Author
-
Wiebe, Jens, Hoppmann, Petra, Kufner, Sebastian, Cassese, Salvatore, Harada, Yukinori, Colleran, Roisin, Xhepa, Erion, Repp, Janika, Schneider, Simon, Ibrahim, Tareq, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert
- Subjects
- *
MYOCARDIAL infarction treatment , *EVEROLIMUS , *DRUG-eluting stents , *MYOCARDIAL revascularization , *HEALTH outcome assessment , *THERAPEUTICS - Published
- 2016
- Full Text
- View/download PDF
41. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention.
- Author
-
Ndrepepa, Gjin, Colleran, Roisin, Braun, Siegmund, Cassese, Salvatore, Hieber, Julia, Fusaro, Massimiliano, Kufner, Sebastian, Ott, Ilka, Byrne, Robert A., Husser, Oliver, Hengstenberg, Christian, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Subjects
- *
PERCUTANEOUS coronary intervention , *CORONARY disease , *TROPONIN , *CONFIDENCE intervals , *BIOMARKERS , *PATIENTS , *CORONARY heart disease surgery , *CARDIOVASCULAR system , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL care , *MEDICAL cooperation , *POSTOPERATIVE period , *PROGNOSIS , *RESEARCH , *ELECTIVE surgery , *SURVIVAL , *TIME , *EVALUATION research , *RETROSPECTIVE studies ,MORTALITY risk factors - Abstract
Background: The prognostic value of high-sensitivity troponin T (hs-TnT) elevation after elective percutaneous coronary intervention (PCI) in patients with or without raised baseline hs-TnT levels is unclear.Objectives: The goal of this study was to assess whether the prognostic value of post-procedural hs-TnT level after elective PCI depends on the baseline hs-TnT level.Methods: This study included 5,626 patients undergoing elective PCI who had baseline and peak post-procedural hs-TnT measurements available. The primary outcome was 3-year mortality (with risk estimates calculated per SD increase of the log hs-TnT scale).Results: Patients were divided into 4 groups: nonelevated baseline and post-procedural hs-TnT levels (hs-TnT ≤0.014 μg/l; n = 742); nonelevated baseline but elevated post-procedural hs-TnT levels (peak post-procedural hs-TnT >0.014 μg/l; n = 2,721); elevated baseline hs-TnT levels (hs-TnT >0.014 μg/l) with no further rise post-procedure (n = 516); and elevated baseline hs-TnT levels with a further rise post-procedure (n = 1,647). A total of 265 deaths occurred: 6 (1.6%) in patients with nonelevated baseline and post-procedural hs-TnT levels; 54 (3.8%) in patients with nonelevated baseline but elevated post-procedural hs-TnT levels; 50 (16.0%) in patients with elevated baseline hs-TnT levels with no further rise post-procedure; and 155 (18.2%) in patients with elevated baseline hs-TnT levels with a further rise post-procedure (p < 0.001). After adjustment, baseline hs-TnT levels (hazard ratio [HR]: 1.22; 95% confidence interval [CI]: 1.09 to 1.38; p < 0.001) but not peak post-procedural hs-TnT levels (HR: 1.04; 95% CI: 0.85 to 1.28; p = 0.679) were associated with an increased risk of mortality. Peak post-procedural hs-TnT findings were not associated with mortality in patients with nonelevated (HR: 0.93; 95% CI: 0.69 to 1.25; p = 0.653) or elevated (HR: 1.24; 95% CI: 0.91 to 1.69; p = 0.165) baseline hs-TnT levels.Conclusions: In patients with coronary artery disease undergoing elective PCI, an increase in post-procedural hs-TnT level did not offer prognostic information beyond that provided by the baseline level of the biomarker. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
42. Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease.
- Author
-
Ndrepepa, Gjin, Colleran, Roisin, Luttert, Anke, Braun, Siegmund, Cassese, Salvatore, Kufner, Sebastian, Hieber, Julia, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Subjects
- *
GAMMA-glutamyltransferase , *DIABETES , *MORTALITY , *CORONARY disease , *CORONARY angiography , *CORONARY heart disease treatment , *PERCUTANEOUS coronary intervention , *PROGNOSIS - Abstract
Objectives The aim of the study was to investigate the association between gamma-glutamyl transferase (GGT) activity and mortality in patients with diabetes mellitus and coronary artery disease (CAD). Design and methods The study included 1448 patients with diabetes and angiography-proven CAD who underwent percutaneous coronary intervention (PCI). Baseline GGT measurements were available in all patients. The primary outcome was 3-year mortality. Results Patients were divided into 3 groups: a group consisting of patients with a GGT activity in the 1st tertile (GGT ≤ 29.4 U/L; n = 487), a group consisting of patients with a GGT activity in the 2nd tertile (GGT > 29.4–52.5 U/L; n = 479) and a group consisting of patients with GGT in the 3rd tertile (GGT > 52.5 U/L; n = 482). Overall, there were 179 deaths: 46 (11.9%), 49 (12.1%) and 84 deaths (21.4%) among patients of the 1st, 2nd and 3rd GGT tertiles, respectively (adjusted hazard ratio [HR] = 1.25, 95% confidence interval [CI] 1.05–1.49, P = 0.011). Cardiac death occurred in 101 patients: 22 (5.8%), 30 (7.2%) and 49 deaths (12.9%) among patients of the 1st, 2nd and 3rd GGT tertiles, respectively (adjusted HR = 1.23 [0.96–1.58], P = 0.104, with risk estimates calculated per standard deviation increase in the logarithmic scale of GGT). GGT improved the risk prediction of models of all-cause (P = 0.020) but not cardiac (P = 0.135) mortality (P values show the difference in C-statistics between the models without and with GGT). Conclusion In patients with diabetes and CAD treated with PCI, elevated GGT was independently associated with the risk of 3-year all-cause mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
- Author
-
de Waha, Antoinette, Stefanini, Giulio G., King, Lamin A., Byrne, Robert A., Serruys, Patrick W., Kufner, Sebastian, Meier, Bernhard, Jüni, Peter, Kastrati, Adnan, and Windecker, Stephan
- Subjects
- *
BIODEGRADABLE plastics , *DRUG-eluting stents , *PEOPLE with diabetes , *MEDICAL polymers , *MYOCARDIAL infarction , *CLINICAL trials , *HEALTH outcome assessment - Abstract
Abstract: Background: There is ongoing debate on the optimal drug-eluting stent (DES) in diabetic patients with coronary artery disease. Biodegradable polymer drug-eluting stents (BP-DES) may potentially improve clinical outcomes in these high-risk patients. We sought to compare long-term outcomes in patients with diabetes treated with biodegradable polymer DES vs. durable polymer sirolimus-eluting stents (SES). Methods: We pooled individual patient-level data from 3 randomized clinical trials (ISAR-TEST 3, ISAR-TEST 4 and LEADERS) comparing biodegradable polymer DES with durable polymer SES. Clinical outcomes out to 4years were assessed. The primary end point was the composite of cardiac death, myocardial infarction and target-lesion revascularization. Secondary end points were target lesion revascularization and definite or probable stent thrombosis. Results: Of 1094 patients with diabetes included in the present analysis, 657 received biodegradable polymer DES and 437 durable polymer SES. At 4years, the incidence of the primary end point was similar with BP-DES versus SES (hazard ratio=0.95, 95% CI=0.74–1.21, P =0.67). Target lesion revascularization was also comparable between the groups (hazard ratio=0.89, 95% CI=0.65–1.22, P =0.47). Definite or probable stent thrombosis was significantly reduced among patients treated with BP-DES (hazard ratio=0.52, 95% CI=0.28–0.96, P =0.04), a difference driven by significantly lower stent thrombosis rates with BP-DES between 1 and 4years (hazard ratio=0.15, 95% CI=0.03–0.70, P =0.02). Conclusions: In patients with diabetes, biodegradable polymer DES, compared to durable polymer SES, were associated with comparable overall clinical outcomes during follow-up to 4years. Rates of stent thrombosis were significantly lower with BP-DES. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
44. Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study
- Author
-
Mehilli, Julinda, Byrne, Robert A., Tiroch, Klaus, Pinieck, Susanne, Schulz, Stefanie, Kufner, Sebastian, Massberg, Steffen, Laugwitz, Karl-Ludwig, Schömig, Albert, and Kastrati, Adnan
- Subjects
- *
SURGICAL stents , *RAPAMYCIN , *CORONARY restenosis , *RANDOMIZED controlled trials , *PACLITAXEL , *ANGIOGRAPHY , *DRUG resistance , *THROMBOSIS - Abstract
Objectives: For patients with sirolimus-eluting stent (SES) restenosis requiring reintervention, we compared a strategy of repeat SES (Cypher, Cordis, Miami Lakes, Florida) implantation with paclitaxel-eluting stent (PES) (Taxus, Boston Scientific, Natick, Massachusetts) implantation. Background: Despite their high anti-restenotic efficacy, the widespread utilization of SES therapy has led to a significant absolute number of patients presenting with SES treatment failure. The optimal treatment strategy for such patients remains unclear. Methods: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study was a randomized, open-label, active-controlled trial conducted among 450 patients with clinically significant in-SES restenosis at 2 centers in Munich, Germany. After pre-treatment with 600 mg clopidogrel, all patients were randomly assigned to either SES or PES implantation. The primary end point was late lumen loss, based on in-stent analysis, at 6- to 8-month follow-up angiography. Secondary end points were binary angiographic restenosis (diameter stenosis >50%) at 6- to 8-month follow-up, target lesion revascularization, the composite of death or myocardial infarction, and definite stent thrombosis at 12 months. Results: Regarding anti-restenotic efficacy, there were no differences between SES and PES in late loss (0.40 ± 0.65 mm vs. 0.38 ± 0.59 mm; p = 0.85), binary restenosis (19.6% vs. 20.6%; p = 0.69), or target lesion revascularization (16.6% vs. 14.6%; p = 0.52). In terms of safety outcomes, the rates of death/myocardial infarction (6.1% vs. 5.8%; p = 0.86) and stent thrombosis (0.4% vs. 0.4%; p > 0.99) were also similar. Conclusions: In cases of SES restenosis, treatment with either repeat SES or switch to PES was associated with a comparable degree of efficacy and safety. Drug resistance at an individual patient level may play a contributory role to the somewhat higher than expected late loss observed with the SES in the current study. (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis 2 [ISAR-DESIRE 2]; NCT00598715) [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
45. TCT-560 Paclitaxel-Eluting Balloon versus conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery. The ISAR-PEBIS randomized trial.
- Author
-
Wittmann, Theresa, Cassese, Salvatore, Groha, Philipp, Steppich, Birgit, Voll, Felix, Hadamitzky, Martin, Ibrahim, Tareq, Kufner, Sebastian, Dewitz, Karl, Kasel, Markus, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, Fusaro, Massimiliano, and Ott, Ilka
- Subjects
- *
DIAGNOSTIC use of transluminal angioplasty , *CORONARY restenosis , *FEMORAL artery , *DIAGNOSIS , *DISEASES - Published
- 2017
- Full Text
- View/download PDF
46. TCT-414 Two-year outcomes of patients with acute coronary syndrome versus stable coronary disease undergoing bioresorbable scaffold implantation.
- Author
-
Wiebe, Jens, Harada, Yukinori, Hoppmann, Petra, Colleran, Roisin, Kufner, Sebastian, Xhepa, Erion, fusaro, massimiliano, Ott, Ilka, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert
- Subjects
- *
TREATMENT of acute coronary syndrome , *CORONARY heart disease treatment , *TISSUE scaffolds , *ARTIFICIAL implants , *CARDIAC research - Published
- 2016
- Full Text
- View/download PDF
47. TCT-399 Impact of post-dilatation on angiographic and clinical outcomes of patients undergoing bioresorbable scaffold implantation in clinical practice.
- Author
-
Wiebe, Jens, Harada, Yukinori, Hoppmann, Petra, Colleran, Roisin, Kufner, Sebastian, Cassese, Salvatore, Xhepa, Erion, Rheude, Tobias, Giacoppo, Daniele, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert
- Subjects
- *
HEART dilatation , *CORONARY angiography , *MEDICAL practice , *TISSUE scaffolds , *CARDIAC patients - Published
- 2016
- Full Text
- View/download PDF
48. FIVE-YEAR CLINICAL OUTCOMES OF SIROLIMUS-ELUTING VERSUS PACLITAXEL-ELUTING STENTS IN HIGH RISK PATIENT SUBSETS: A POOLED ANALYSIS OF 3 RANDOMIZED TRIALS
- Author
-
Birkmeier, Katrin A., Kastrati, Adnan, Byrne, Robert A., Tiroch, Klaus, Holle, Heidrun, Schulz, Stefanie, Kufner, Sebastian, Massberg, Steffen, Laugwitz, Karl-Ludwig, Schömig, Albert, Mehilli, Julinda, and Herzzentrum, Deutsches
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.